Symphogen Financing Largest for Private European Biotech
By Tom Wall
Friday, January 7, 2011
Symphogen A/S, of Copenhagen, Denmark, has raised what it said is the largest financing ever for a private European biotech company with a $131 million preferred stock placement.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.